• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

alexionpharmaceuticals

Leukemia trial to match patients with drugs based on genetic biomarkers

July 19, 2017 By Sarah Faulkner

Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational […]

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: alexionpharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Celgene, Gilead Sciences

Braeburn names former Teva exec as new president, CEO | Personnel Moves – June 14, 2017

June 14, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: alexionpharmaceuticals, AstraZeneca plc, Biogen, Boston Scientific, Braeburn Pharmaceuticals, ctibiopharma, cytrx, Dicerna Pharmaceuticals, GlaxoSmithKline plc, Merrimack Pharmaceuticals, Novartis, Ocular Therapeutix, Sanofi-Aventis, Teva Pharmaceuticals, uniqure

Insulet brings on new chief commercial exec | Personnel Moves – June 5, 2017

June 5, 2017 By Sarah Faulkner

Insulet

Insulet (NSDQ:PODD) last month named Bret Christensen as its chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy. He most recently served as GM of Myriad Genetics’ preventive care business division. He has also worked as VP of sales and marketing of the gynecologic surgical products unit at Hologic. “I […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: aldevron, alexionpharmaceuticals, alucentmedical, Asterias Biotherapeutics, Biogen, Eli Lilly & Co., Insulet, Novartis, Pacira Pharmaceuticals, pierispharmaceuticals

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS